Press Release

Theravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference

DUBLIN, Sept. 2, 2025 /PRNewswire/ — Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced that management will participate at the H.C. Wainwright 27th Annual Global Investment Conference in New York City.

Rick Winningham, CEO, will participate in a Fireside Chat on Tuesday, September 9Ā atĀ 1:30 PM EDTĀ (10:30 AM PDTĀ /Ā 6:30 PM IST).

Management will be hosting in-person meetings during the event. Interested investors should contact their H.C. Wainwright representative to request a meeting.

A live webcast of the event may be accessed here or on the “Events and Presentation” page under the Investors section on Theravance.com. A replay of the webcast will be archived on the Company’s website for 30 days.

AboutĀ Theravance BiopharmaĀ 

Theravance Biopharma, Inc.’sĀ focus is to deliverĀ Medicines that Make a Difference® in people’s lives. In pursuit of its purpose,Ā Theravance BiopharmaĀ leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.

For more information, please visitĀ www.theravance.com.
THERAVANCE BIOPHARMAĀ®, THERAVANCEĀ® and the Cross/Star logo are registered trademarks of theĀ Theravance BiopharmaĀ group of companies (in theĀ U.S.Ā and certain other countries).

YUPELRIĀ® is a registered trademark ofĀ Viatris Specialty LLC. Trademarks, trade names or service marks of other companies appearing on this press release are the property of their respective owners.

Contact:
[email protected]
650-808-4045

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-present-at-the-hc-wainwright-27th-annual-global-investment-conference-302543498.html

SOURCE Theravance Biopharma, Inc.

Author

Leave a Reply

Related Articles

Back to top button